Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

NCT03801434 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT03801434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03801434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 15, 2019
Completion date
February 28, 2029
Enrollment
8 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bcr-jak2 fusion protein expression, blasts 20 percent or less of peripheral blood white cells, blasts more than 5 percent of bone marrow nucleated cells, blasts more than 5 percent of peripheral blood white cells, blasts under 20 percent of bone marrow nucleated cells, chronic eosinophilic leukemia, not otherwise specified, eosinophilia, hepatomegaly, hypereosinophilic syndrome, jak2 gene mutation, splenomegaly, tel-jak2 fusion protein expression